Obinutuzumab (Gazyva) for MMN — Evidence & Clinical Trials

Overview

Treatment Details

Mechanism of Action

A monoclonal antibody targeting CD20, a surface marker on B cells, that depletes B cells via antibody-dependent cellular cytotoxicity — a more potent depletion mechanism than earlier-generation anti-CD20 antibodies. Already FDA-approved for lupus nephritis (kidney involvement) since October 2025, and under FDA review for broader SLE use following positive Phase III ALLEGORY trial results, with a decision expected by December 2026.

Dosing Notes

Intravenous infusion administered on a defined induction and maintenance schedule per the approved lupus nephritis regimen.

Treatment Type

pharmaceutical

Clinical Evidence

What the Evidence Shows

Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.

High: Supported by multiple robust studies or regulatory approval

Moderate: Supported by limited controlled studies or consistent case series

Low: Based on case reports, expert opinion, or early-phase data only

Moderate ConfidenceSupported by limited controlled studies or consistent case series

The Phase III ALLEGORY study found that nearly 77% of adults with moderate-to-severe SLE treated with obinutuzumab plus standard therapy achieved a clinically relevant SRI-4 improvement at 52 weeks, compared to about 54% with placebo. FDA is expected to issue a decision on broader SLE approval (beyond its existing lupus nephritis approval) by December 2026.

Verified Jul 2026

Institutional Research

FDA Accepts Supplemental Biologics Application for Gazyva in Systemic Lupus Erythematosus

Published April 2026

View source ↗

Clinical Trials

Linked Trials1 trial

No registry ID — unregistered program

Proportion of patients achieving a clinically relevant improvement (≥4 point increase) in SLE Responder Index-4 (SRI-4) at 52 weeks

Target enrollment: 500 participants